prostate cancer - search results

This study revealed that antiandrogen therapy induces viral mimicry responses that are crucial for antitumor activity.

Incorporating genetic factors that influence prostate-specific antigen (PSA) level into prostate cancer screening may help reduce unnecessary invasive testing and improve the detection of aggressive disease.

Researchers at CAS Center for Excellence in Molecular Cell Science of the Chinese Academy of Sciences demonstrated in mouse models the oncometabolite role of progesterone in advanced prostate cancer and strategies to eliminate its oncogenic effect.

Black men with prostate cancer may respond well to androgen deprivation therapy (ADT)-based regimens, but they are less likely to receive such therapy than non-Blacks, according to a new multi-institutional retrospective analysis.

A Phase III clinical trial led by scientists at Massachusetts General Hospital showed that adding darolutamide to androgen-deprivation therapy and chemotherapy extended the survival of men with metastatic, hormone-sensitive prostate cancer.

In a first-of-its-kind study on dogs with naturally occurring prostate cancer, scientists have discovered that blocking CCR4 expressing regulatory T cells that infiltrate tumors and prevent other immune cells from annihilating tumor cells, may be a promising therapeutic strategy for advanced prostate cancer in dogs and a subset of human patients.

The analysis, which combined individual patient data from three different cohorts, showed that men receiving high-dose external beam radiotherapy (EBRT) alone may benefit from at least 18 months of ADT whereas those who receive EBRT plus a brachytherapy boost may be optimally managed with 18 months of ADT or less.

A large study led by the Karolinska Institute in Sweden shows that artificial intelligence can be used to accurately diagnose and grade prostate cancer in a way that is generalizable across different populations.

The launch of the clinical trial wholly sponsored by 23andMe is a pivotal achievement for the company’s therapeutic development division, which was started in 2015. But in 2020 GSK launched a trial of a drug candidate that came out of its collaboration with 23andMe, which started in 2018.

A meta-analysis of radiation therapy trials by UCLA Jonsson Comprehensive Cancer Center researchers showed that black men with more aggressive disease appeared to have better outcomes than their white counterparts.